Other pharmacological approaches, such as statins, ACE inhibitors, PCSK9 inhibitors, or DPP-4, have not demonstrated many benefits in aortic stenosis outcomes, as mentioned previously. This evidence concerns the gene PCSK9 and aortic stenosis.